Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexis Jimenez

Interventional Pain Medicine Jacksonville, FL Medical Doctor

NPI 1942441746 CMS profile 42516

4796 Hodges Blvd, Suite 101, Jacksonville, FL 32224

Open in the dashboard

General payments

$17,755

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexis Jimenez of Jacksonville, FL is reported in the CMS Open Payments database as having received $17,755 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,143 39
2024 General $2,190 47
2023 General $2,447 68
2022 General $3,754 62
2021 General $3,090 70
2020 General $1,415 71
2019 General $2,716 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexis Jimenez
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alexis Jimenez were reported at $2,143. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alexis Jimenez Interventional Pain Medicine median Middle half National median
2019 $2,716 $684 $216–$2,079 $163
2020 $1,415 $382 $122–$1,109 $114
2021 $3,090 $552 $167–$1,554 $132
2022 $3,754 $605 $187–$1,924 $149
2023 $2,447 $671 $195–$1,915 $160
2024 $2,190 $684 $206–$1,837 $164
2025 $2,143 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $6,570 120 payments
  2. Medtronic, Inc. $1,771 29 payments
  3. Nevro Corp. $845 21 payments
  4. Stimwave Technologies Incorporated $624 10 payments
  5. Relievant Medsystems, Inc. $544 7 payments
  6. Medtronic USA, Inc. $496 13 payments
  7. SPR Therapeutics, Inc $478 8 payments
  8. Avanos Medical $441 4 payments
  9. Abbott Laboratories $440 15 payments
  10. Amgen Inc. $412 10 payments
  11. Other $5,134 238 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,513 462 payments
  2. Travel and Lodging $2,130 8 payments
  3. Education $112 5 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $2,040 39 payments
  2. Superion Indirect Decompression System $1,621 14 payments
  3. WAVEWRITER ALPHA $886 7 payments
  4. INTELLIS ADAPTIVESTIM $764 18 payments
  5. Intracept $647 8 payments
  6. AIMOVIG $563 18 payments
  7. General - Pain Management $504 7 payments
  8. SPRINT PNS System $478 8 payments
  9. StimQ Freedom 8A Receiver Kit Channel A US w Receiver $463 6 payments
  10. Freedom 8A Receiver Kit Channel A US w Receiver $463 6 payments
  11. Other $12,192 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

8,486

Median for Interventional Pain Management: 1,220

Drug cost

$524,302

Median for Interventional Pain Management: $39,344

Branded share of claims

59.5%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 118 $98,117
Percocet Oxycodone Hcl/Acetaminophen Brand 24 $90,915
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 2,107 $76,096
Xtampza Er Oxycodone Myristate Brand 119 $57,525
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,907 $49,250
Buprenorphine Generic 161 $34,197
Pregabalin Generic 839 $17,675
Morphine Sulfate Er Morphine Sulfate Brand 415 $9,758
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 93 $9,416
Movantik Naloxegol Oxalate Brand 18 $9,309

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 109 billing codes

Paid by Medicare

$2,280,641

Of which drugs: $23,787

Medicare patients

2,402

Average age 74

Services billed

44,434

1,416 women, 986 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 59%
Diabetes 50%
Ischemic heart disease 50%
Chronic kidney disease 46%
Heart failure 42%
COPD 39%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 159 1,171 $847
Injection, ketorolac tromethamine, per 15 mg J1885 Office 17 90 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $25
$25 — —
MOVANTIK
  • Valinor Pharma, LLC $19
$19 18 —
UBRELVY
  • AbbVie, Inc. $13
$13 — —
QULIPTA
  • AbbVie, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record